Compounds in this category share a common pharmacological anchor but diverge meaningfully in half-life, receptor selectivity, and tolerability profile. A compound's published dose range is rarely interchangeable with its sibling's; the molecule matters.
Where human trial data exists, we lean on it. Where only preclinical or open-label data exists, we flag the limitation in plain language. We do not infer efficacy from mechanism alone, mechanism is a starting question, not an answer.
Citations for each entry reference Phase 2+ clinical data where available, peer-reviewed preclinical work otherwise. Commercial white-papers are excluded.
The contemporary cognitive-nootropic peptide catalogue is dominated by compounds developed in the Russian Academy of Sciences research tradition. Semax is a synthetic heptapeptide derived from the ACTH(4-10) fragment and carries Russian clinical registration for ischemic-stroke recovery. Selank is a synthetic heptapeptide derived from the immune-signalling tetrapeptide tuftsin and is studied as a non-sedating anxiolytic. DSIP (delta-sleep-inducing peptide) sits adjacent to the cluster with a thinner contemporary trial base. Outside the Russian programme, Cerebrolysin is the major non-synthetic entry — a porcine-derived peptide-and-amino-acid mixture characterised by activity rather than by a single defined sequence. The regulatory histories diverge meaningfully across jurisdictions; the underlying mechanism research converges.
Brain-derived neurotrophic factor and nerve growth factor are the two neurotrophins most directly implicated in adult synaptic plasticity, hippocampal neurogenesis, and neuronal-survival signalling under stress. The cognitive-nootropic peptides cluster around this axis: Semax administration in rat models drives BDNF and TrkB transcript upregulation in the hippocampus, frontal cortex, and retina, with independent replication across multiple research groups. Cerebrolysin acts as a neurotrophic-mimetic — its active peptide fragments cross the blood-brain barrier and mimic BDNF, GDNF, NGF, and CNTF activity. The mechanism walkthroughs live in the Semax + Selank BDNF article and the Cerebrolysin neurotrophic research article.
The cognitive-nootropic cluster differentiates from the GLP-1 metabolic and GH-secretagogue clusters in three ways. First, the registered-drug evidence base is dominated by Cerebrolysin trials (CASTA 2012 negative on overall mRS, CARS 2016 positive on motor-recovery ARAT, Alvarez 2011 positive on ADAS-cog in moderate-to-moderately-severe Alzheimer's) rather than by metabolic-class CVOTs. Second, route of administration is split: the Russian-programme compounds use intranasal delivery for direct CNS access, while Cerebrolysin uses IV or IM infusion. Third, Western replication of the Russian-tradition compounds is limited; researchers selecting from this cluster should weight Phase 3-equivalent evidence (Cerebrolysin) against mechanism-clean compounds with smaller human-trial bases (Semax, Selank).
BDNF and NGF expression is upregulated by Semax, Selank, and Cerebrolysin through distinct upstream pathways — Semax via ACTH(4-10) receptor activity, Selank via tuftsin-pathway transcriptomic effects, Cerebrolysin via direct neurotrophic-mimetic peptide fragments. The convergent downstream effect is hippocampal and cortical neurogenesis support.
Cerebrolysin has the strongest registered-drug evidence base — CASTA 2012 negative on overall mRS, CARS 2016 positive on motor-recovery ARAT. Semax carries Russian clinical registration for ischemic stroke; Western evidence is preclinical. DSIP has the thinnest contemporary clinical literature in this cluster.
The Russian-programme compounds (Semax, Selank) use intranasal delivery for direct CNS access at low microgram doses. Cerebrolysin uses IV or IM infusion at the larger mL volumes characteristic of biologic preparations. Research protocols match the validated administration route per compound rather than substituting.
